Filter By:

Results

CTN 145: rIL-2 to slow progression of HIV (SILCAAT)

A Phase III, multicentre, randomized study of the biological and clinical efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with low CD4+ counts under active antiretroviral therapy(SILCAAT): Trial results

Learn More

Results

CTN 143: Twice Daily Indinavir plus Ritonavir

An Open-Label, Randomized, 48-Week Study to Compare the Safety, Tolerability, and Surrogate Marker Activity of an Indinavir Sulfate (800 mg q8h) Regimen versus BID Indinavir Sulfate (800 mg q12h) plus Ritonavir (100 mg q12h) Regimen in HIV-Infected Individuals Having Previously Achieved Viral Load Suppression below the Limit of Detection with a Triple Antiretroviral Treatment Regimen Containing Indinavir Sulfate in Combination with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [BEST]: Trial results

Learn More
Canadian Association for HIV Research

CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.